112 results about "Orally disintegrating tablet" patented technology

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The invention belongs to the technical field of medicines, and particularly relates to a melogabalin besylate orally disintegrating tablet coated with powder. The powder-coated melogabalin besylate orally disintegrating tablet provided by the invention has good wet stability, effectively masks the bitter taste of the raw material medicines, obviously improves the taste, has good dissolution behavior, shows extremely rapid dissolution in key media, is beneficial to the absorption of melogabalin besylate by the body, and can be used for preparing the oral disintegrating tablet for treating melogabalin besylate. The melogabalin besylate orally disintegrating tablet provided by the invention has a good application prospect.

The invention belongs to the technical field of medicine, and particularly relates to an aprepitant nanocrystalline composition and a preparation method and application thereof.The aprepitant and a sucrose solution are mixed, a stabilizer is added to obtain a solution to be ground, the solution to be ground is ground through a wet grinding process, and the aprepitant nanocrystalline composition is obtained; uniformly mixing the suspension with a spray drying protective agent and a flow aid to obtain a mixed solution, and drying and curing the mixed solution by adopting a spray dryer to obtain the aprepitant nanocrystal composition in the form of a dry suspension, and directly spray-drying the suspension, uniformly mixing the suspension with a skeleton agent and an adhesive, adding water to a constant volume, carrying out vacuum degassing, and carrying out pre-freezing and freeze-drying to obtain the freeze-dried orally disintegrating tablet type aprepitant nanocrystal composition.

The application belongs to the technical field of pharmaceutical preparations, and specifically provides a kind of indobufen freeze-dried oral disintegrating tablet and a preparation method thereof.The freeze-dried oral disintegrating tablet contains indobufen and xanthan gum, and the freeze-dried oral disintegrating tablet can be obtained by freeze-drying technology after the above components are prepared into a suspension.The freeze-dried oral disintegrating tablet provided by the application has the technical characteristics of good properties, complete demolding, high drug loading, good content uniformity, rapid disintegration and rapid dissolution, and can meet the needs of rapid anti-platelet therapy in acute thrombosis events.

The invention provides a hematopoietic anti-aging active component extracted from fish embryos as well as an extraction method and application of the hematopoietic anti-aging active component, and belongs to the technical field of active component extraction. The hematopoietic anti-aging active component is extracted from fish embryos which are developed from fish fertilized eggs to the earlier stage of incubation at the optimum temperature and stop development through rapid freezing, and is rich in exosomes, active protein, peptide, chondroitin sulfate, hyaluronic acid, small molecule metabolites, various active factors and the like, and all the nutritional active components are matched with one another, so that the effects of resisting aging and resisting aging are achieved. The cartilage development can be supported, the joint health is ensured, the hematopoietic effect is enhanced, and the skin aging is delayed. The orally disintegrating tablet containing the hematopoietic anti-aging active component can avoid inactivation of bioactive substances caused by high temperature, and the biological activity of the hematopoietic anti-aging active component is reserved to the maximum extent. The hematopoietic anti-aging active component and the orally disintegrating tablet are simple in preparation process and remarkable in hematopoietic anti-aging effect.

1. Name of the product in this design: Pharmaceutical Packaging Box (Salbutamol Sulfate Orally Disintegrating Tablets for Children). 2. Purpose of this design: This design is used for packaging salbutamol sulfate orally disintegrating tablets. 3. The key design features of this product are the combination of pattern and color. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color.

The invention discloses a medicinal slow-release antistatic coating solution and a preparation method and application thereof, and belongs to the technical field of medicinal preparations, the medicinal slow-release antistatic coating solution comprises the following components by weight: 1.2-2.0% of an anti-sticking agent; 0.4%-0.8% of a plasticizer; 0.04 to 0.22% of a lubricant; 3.0 to 5.0 percent of ethyl cellulose; the balance is ethanol or an ethanol aqueous solution; and the lubricant is long-chain saturated fatty acid or long-chain saturated fatty glyceride with the carbon number of C12-C22. The coating liquid has an antistatic effect and can obviously improve electrostatic adsorption and particle bonding phenomena in the coating process, small-diameter medicine particles are coated by using the coating liquid, a prepared coating film is complete, smooth and crack-free, the slow-release effect is good, enteric slow-release particles and orally disintegrating tablets can be prepared after an enteric coating is further overlaid, and the application range is wide. And the preparation method has a good application prospect in the development of small-diameter functional particles and orally disintegrating tablets.

The present application belongs to the technical field of oral solid preparation, and particularly relates to a mosapride citrate orally disintegrating tablet and a preparation method thereof. Raw and auxiliary materials comprise mosapride citrate, a filling agent, a disintegrating agent, a glidant, a lubricant and a flavoring agent. The present application screens and optimizes the auxiliary material formula, adopts dry granulation, optimizes the preparation process, improves the compressibility and fluidity of the material, saves energy, improves the production quality and stability, makes the prepared orally disintegrating tablet disintegrate rapidly, has excellent taste, greatly improves the medication compliance of patients, simultaneously improves the drug dissolution and improves the bioavailability. In addition, compared with other types of solid oral preparations of the product, the mosapride citrate orally disintegrating tablet is particularly suitable for the elderly and patients with difficulty in swallowing, and provides convenience in special and urgent situations such as lack of drinking water for taking medicine.

The present invention relates to an orodispersible tablet manufactured by a wet granulation method comprising pregabalin or pharmaceutically acceptable salts thereof, at least one disintegrant, at least one diluent, at least one binder, at least one glidant, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The invention discloses a rosaxostat orally disintegrating tablet and a preparation method thereof. The preparation method of the orally disintegrating tablet is selected from one of a freeze-drying method, a tabletting method and a melting method. The prescription of the freeze-drying method comprises the rosaxostat or rosaxostat salt, a skeleton supporting agent, an adhesive, a suspending aid and a surfactant. According to the preparation formula and the preparation process, the defect that the content uniformity of the prepared tablets is poor due to the fact that the uniformity of intermediate liquid medicine is poor in the preparation process can be overcome, and the disintegration time limit of the rosaxostat orally disintegrating tablets, especially the rosaxostat freeze-dried orally disintegrating tablets, is further prolonged; the medicine is especially suitable for old people, children, patients with dysphagia and people with inconvenience in taking water to take medicine; the bioavailability is high; the rosaxostat orally disintegrating tablet is simple in material, moderate in tablet weight, good in appearance, good in taste, fast in disintegration, simple in preparation process and suitable for industrial mass production.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an etoricoxib orally disintegrating tablet and a preparation method thereof. The etoricoxib orally disintegrating tablet comprises etoricoxib, a filling agent, a disintegrating stabilizer, a wetting agent and a lubricating agent, the disintegration stabilizer is composed of polacrilin potassium, diethylaminol and glycine. The preparation process adopts wet granulation. According to the invention, the problem of balance among disintegration speed, stability and taste of the traditional orally disintegrating tablet is solved, and the orally disintegrating tablet has clinical transformation value.

The present invention relates to an orodispersible tablet comprising carbamazepine or pharmaceutically acceptable salts thereof, at least one disintegrant, at least one diluent, at least one binder, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients 5 exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The application provides a folic acid-containing composition and application, an orally disintegrating tablet and a preparation method. The folic acid-containing composition comprises folic acid raw materials, escitalopram oxalate and memantine hydrochloride. The weight ratio of the folic acid raw materials, the escitalopram oxalate and the memantine hydrochloride is (0.4-5):(10-20):(5-30). The folic acid raw materials comprise one or more of folic acid and derivatives thereof. The folic acid raw materials, the escitalopram oxalate and the memantine hydrochloride are used in a specific proportion, can be synergistic, can effectively treat post-stroke central neuropathic pain with depression, and can prevent recurrence of stroke, and are beneficial to post-stroke rehabilitation.

The invention discloses a preparation method for prolonging the validity period of erythromycin ethylsuccinate orally disintegrating tablets. The preparation method comprises the following steps: sequentially putting low-substituted hydroxypropyl cellulose, microcrystalline cellulose, aspartame, carboxymethyl starch sodium and polyvinylpolypyrrolidone into a wet granulation mixer, covering with a cover, starting equipment, carrying out low-speed dry mixing for 3 minutes, slowly adding low-concentration hydroxypropyl methylcellulose slurry from a feed port of a pot cover, and carrying out low-speed wet mixing for 3 minutes; stopping the machine, opening the cover, scraping powder on the inner surface of the pot cover and the periphery of the inner side of the pot by using a clean scraper, adding erythromycin ethylsuccinate raw materials, covering the cover, starting equipment, carrying out low-speed wet mixing for 3 minutes, and carrying out high-speed wet mixing for 2 minutes. By improving the medicine production process, the stability and durability of the medicine are improved, so that the validity period of the medicine is prolonged, and meanwhile, the effectiveness and safety of the medicine can still be kept within the prolonged validity period.

The present invention discloses a buclizine hydrochloride orally disintegrating tablet composition and a preparation method thereof, which relates to the technical field of preparations. The buclizine hydrochloride orally disintegrating tablet composition, calculated by weight parts, comprises the following components: 4 parts of buclizine hydrochloride fine powder, 60-100 parts of a diluent, 10-30 parts of a disintegrant, 0.5-2 parts of a binder, 1-3 parts of a glidant, 1-5 parts of a sweetening agent, 0.5-5 parts of a lubricant, and 0.5-1.5 parts of a solubilizer. The present invention uses buclizine hydrochloride in combination with a solubilizer, so that the dissolution of buclizine hydrochloride is greatly improved. In combination with other components in the material, low-substituted hydroxypropyl cellulose and cross-linked polyvinylpyrrolidone, the disintegration time limit is further improved.

A cellulose composition containing cellulose, glucose and sorbitol, wherein a total content of glucose and sorbitol is 0.7 mg or more and 4.0 mg or less per 5 g of the cellulose composition. A tablet contains the cellulose composition. An orally disintegrating tablet contains the cellulose composition.

The invention discloses sunflower disc holocellulose, a preparation method and application of the sunflower disc holocellulose as a disintegrating agent, and belongs to the technical field of pharmaceutic adjuvants. The preparation method comprises the following steps: crushing sunflower heads, sieving, degreasing to obtain sunflower head powder, mixing the sunflower head powder with an alkali solution, and extracting; and bleaching the washed and dried filter residues, washing, drying, and modifying with a biological enzyme to obtain the sunflower disc holocellulose disintegrating agent. The disintegrant is prepared from agricultural wastes as raw materials through alkali extraction, bleaching, enzyme modification and other processes, the sunflower disc holocellulose is used as an efficient pharmaceutical adjuvant disintegrant, rapid disintegration of tablets such as orally disintegrating tablets and the like can be achieved, the disintegration effect can be equivalent to that of commercially available efficient disintegrants, and high-value utilization of the agricultural wastes is achieved. The prepared disintegrating agent is high in water absorption performance, good in expansion performance, good in biocompatibility and environment-friendly, and has important practical significance for fully utilizing biomass resources and solving the problem of medicine auxiliary material sources.

To provide bepotastine-containing granules that are compact and have excellent bitterness-masking properties.SOLUTION: A spherical granule is formed by a spherical core portion containing bepotastine or a salt thereof as an active ingredient and a coating portion that covers the spherical core portion and contains a masking layer containing a water-insoluble polymer. The volume-based cumulative 50% particle size (D50) of the spherical granule may be 250 μm or less (particularly 200 μm or less). The proportion of the bepotastine or a salt thereof in the spherical granule may be 20 to 80 mass%. The water-insoluble polymer may contain a (meth)acrylic polymer having an ammonio methacrylate unit. The masking layer may further contain an inorganic compound. The proportion of the bepotastine or a salt thereof in the spherical core may be 50 mass% or more. The spherical core portion may be a spherical particle of bepotastine or a salt thereof. An oral preparation (particularly an orally disintegrating tablet) containing the spherical granule may be prepared.SELECTED DRAWING: None

Provided herein are methods of treating a seizure disorder in a subject in need thereof comprising administering seletracetam to the subject intranasally, buccally, or sublingually. Also provided are methods of treating a pain, neurological, or psychiatric disorder, and methods of administering seletracetam to a subject comprising administering seletracetam to the subject intranasally, buccally, or sublingually. Various pharmaceutical formulations comprising seletracetam, e.g., an orally disintegrating tablet and a mucoadhesive film, and a nasal spray device or oromucosal spray device comprising seletracetam are also provided.

The invention belongs to the technical field of medicines, and particularly relates to a fenerenone orally disintegrating tablet and a preparation method thereof. The active component of the fenerenone orally disintegrating tablet is fenerenone, and the fenerenone orally disintegrating tablet comprises the following components in percentage by weight: 3-45% of fenerenone, 1-5% of magnesium stearate, 1-5% of magnesium stearate, 1-5% of 48-70% of a filler; 0.5-2% of an adhesive; 1-4% of a flow aid; 1-4% of a lubricant; the composition comprises the following components in percentage by weight: 0-15% of a first disintegrating agent, 2-6% of a second disintegrating agent and 2-6% of a third disintegrating agent, the first disintegrating agent, the second disintegrating agent and the third disintegrating agent are the same or at least two of the first disintegrating agent, the second disintegrating agent and the third disintegrating agent are different, preferably, the weight content of the fenerenone is 10-15%, and / or the weight content of the filling agent is 59-70%. The finerenone orally disintegrating tablet disclosed by the invention is suitable for being taken by diabetics, and has the advantages of high disintegration and dissolution speed, stable finished product quality, no need of being taken with water and strong patient compliance; in addition, the finerenone orally disintegrating tablet disclosed by the invention is simple in preparation process, low in cost and suitable for large-scale production.

The present invention discloses a new formulation composition of apixaban with obvious clinical advantages and a preparation method thereof, belonging to the field of pharmaceutical preparations. The new formulation composition of apixaban comprises the following components: apixaban, a filler, a binder, a disintegrant, a solubilizer, a glidant, a lubricant and a flavoring agent; wherein, the binder is hydroxypropyl cellulose, and calculated by weight percentage, the proportion of the binder is 1.0-3.0%. The new formulation composition of apixaban provided by the present invention has a short disintegration time in the oral cavity and does not need to be swallowed with water, thereby improving the convenience and compliance of administration, improving the medication safety of special populations, and providing a better choice for patients with dysphagia and / or those who need to crush tablets and then take them orally or by nasogastric feeding after surgery.

The invention discloses an orally disintegrating tablet and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The orally disintegrating tablet comprises 0.5-30 wt% of an active component, 25-35 wt% of an adhesive, 25-65 wt% of a filler and 1-10 wt% of a suspending aid, the active component comprises an antipsychotic raw material medicine and / or an antiepileptic raw material medicine. The void ratio of the orally disintegrating tablet is controlled to be 40-90%, even if the active ingredient is a low-solubility raw material medicine, the orally disintegrating tablet also has the fluffy feeling like puffed food, good taste and pleasant experience, meanwhile, the provided orally disintegrating tablet enables the medicine to be rapidly released in the oral cavity, the disintegration time in the oral cavity is shorter than 5 s, and the orally disintegrating tablet is suitable for oral administration. Compared with the oral cavity disintegration time of about 20s of disintegrating tablets and the oral cavity disintegration time of about 15s of oral soluble films in the prior art, the tablet has remarkable advantages, improves the compliance of patients, and greatly reduces the possibility of Tibetan medicine and vomiting of the patients especially for patients with dysphagia.

The application belongs to the technical field of medicine, and particularly relates to a kind of opicapone oral disintegrating tablets and a preparation method thereof.The active component of the opicapone oral disintegrating tablet is opicapone, and the components are as follows according to weight percentage: opicapone 15-25%; filler 60-70%; glidant 1-4%; lubricant 1-4%; first disintegrating agent 2-6%; and second disintegrating agent 2-6%, wherein the first disintegrating agent and the second disintegrating agent are different, and preferably, the weight content of the opicapone is 15-20%.The opicapone oral disintegrating tablet of the application is suitable for the adjuvant therapy of levodopa / carbidopa, has a fast disintegration rate, stable product quality, does not need to be taken with water, and has strong patient compliance; in addition, the preparation process of the opicapone oral disintegrating tablet of the application is simple, has low cost, and is suitable for mass production.

The invention discloses a quick-acting heart-saving freeze-dried orally disintegrating tablet and a preparation method thereof, and relates to the technical field of medicines, the quick-acting heart-saving freeze-dried orally disintegrating tablet is prepared from the following materials through freeze drying: a ligusticum wallichii extract, a borneol clathrate compound, a freeze-dried proppant, and an optional sweetening agent and / or thickening agent, the borneol clathrate compound is a clathrate compound prepared from cyclodextrin or a derivative thereof through a clathration technology. According to the freeze-dried orally disintegrating tablet and the preparation method thereof, the inclusion compound of the borneol and the cyclodextrin derivative is prepared firstly, then the inclusion compound and other raw and auxiliary materials are prepared into the freeze-dried orally disintegrating tablet according to a specific process, the stability of the borneol content in a final product can be effectively guaranteed, and cyclodextrin or the cyclodextrin derivative is selected from at least one of beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin and sulfobutyl-beta-cyclodextrin. Meanwhile, the absolute ethyl alcohol for dissolving the borneol is removed during preparation of the inclusion compound, a special freeze dryer is not needed, the safety problem of equipment operation is avoided, and the production cost is reduced.

The invention provides a lurasidone orally disintegrating tablet and a preparation method thereof, and relates to the technical field of pharmaceutical preparations. The lurasidone orally disintegrating tablet is prepared from the following components in parts by mass: 15 to 23 parts of lurasidone hydrochloride, 60 to 70 parts of a filling agent, 1.5 to 3.5 parts of an adhesive, 9 to 12 parts of a disintegrating agent, 0.1 to 1 part of a sweetening agent and 0.5 to 2 parts of a lubricating agent, the filling agent comprises mannitol and microcrystalline cellulose; the mass ratio of the mannitol to the microcrystalline cellulose is 1: (1-5). The lurasidone orally disintegrating tablet prepared by the preparation method disclosed by the invention is fast in disintegration, high in dissolution rate and better in stability.

The application provides a butylphthalide sublingual tablet and a preparation method thereof, wherein the butylphthalide sublingual tablet contains the following components by weight percentage based on 100% of the total weight of the butylphthalide sublingual tablet: 10%-25% of an active substance, 10%-40% of an emulsifier, 10%-75% of an excipient, 0.2%-2% of a binder, 1%-30% of a sweetening agent, and 0.1%-2% of a fragrance agent; and the active substance is butylphthalide or a butylphthalide derivative. The application does not need to add a disintegrating agent, the auxiliary materials used are water-soluble, and the amount is small, so that the preparation can be rapidly disintegrated in the oral cavity without grit feeling, thereby overcoming the slow disintegration in the oral cavity and grit feeling of the oral disintegration tablet prepared by using a direct compression method.